Musa Civak

Musa Civak

Auto-generated profile, based on publicly available information

Musa Civak

Ankara City Hospital Department of Internal Medicine Ankara 06800 Turkey

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2021 in Future Virology
Verified
Journal Article
Open access
EGEmin Gemcioglu
Emin Gemcioglu
MDMehmet Davutoglu
Mehmet Davutoglu
RCRamis Catalbas
Ramis Catalbas
BKBerkan Karabuğa
Berkan Karabuğa
EKEnes Kaptan
Enes Kaptan
IAIhsan Ates
Ihsan Ates
Aim: COVID-19 is a pandemic that causes high morbidity and mortality, especially in severe patients. In this study, we aimed to search and explain the relationship between biochemical markers, whic... Graphical abstract

10 September 2024 in Tuberk Toraks
Verified
Journal Article
Open access
HKHatice Kilic
Hatice Kilic
EAEmine Argüder
Emine Argüder
MCMusa Ci̇vAk
Musa Ci̇vAk
EGEmin Gemci̇oĞlu
Emin Gemci̇oĞlu
AKAyşe Kaya Kalem
Ayşe Kaya Kalem
AKAYSEGÜL KARALEZLI
AYSEGÜL KARALEZLI
It is known that the use of inhaled corticosteroids increases the incidence of pneumonia in patients followed up with the diagnosis of chronic asthma and chronic obstructive pulmonary disease (COPD). This study aimed to investigate the contribution of inhaled steroid use to pneumonia severity and mortality in cases with COVID-19 pneumonia. The study is a retrospective, observational study. Among the cases admitted to the pandemic clinic, patients diagnosed with COVID-19 pneumonia were included. The plan was to compare cases who received and did not receive inhaled corticosteroids in terms of pneumonia severity and mortality. In order to define risk factors for mortality, univariate and multivariable negative binomial regression analyses were performed. In our study, it was observed that n= 540 (75%) cases did not receive inhaled corticosteroids (group 1), and 180 (25%) cases used inhaled corti costeroids (group 2). Group 1 and group 2 cases were compared in terms of pneumonia severity with no significant difference between the two groups (p= 0.11). Then, risk factors affecting mortality in all cases were examined with univariate analyses. Increasing age, applying mechanical ventilation, having severe pneumonia, having interstitial lung disease, and applying prone position were found to be statistically significant factors in mortality (p < 0.05). In conclusion, in our study, it was observed that the use of inhaled corticosteroids did not increase the severity of pneumonia and mortality. It was thought that the treatment they received could be continued when the patients treated with inhaled corticosteroids due to asthma and COPD had COVID-19 pneumonia.